cyrilzakka/clinical-trials huggingface dataset:
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Tourette Syndrome

This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Tourette Syndrome

This patient funded trial aims to study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells (UC-MSCs) for the treatment of Tourette Syndrome. Patients will receive a single intravenous infusion of UC-MSCs. The total dose will be 100 million cells. Patients will be evaluated within one month pre treatment and at 1, 6, 12, 24, 36, and 48 months post treatment for safety and efficacy.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of Tourette Syndrome
* Understanding and willingness to sign a written informed consent document

Exclusion Criteria:

* Active infection
* Active cancer
* Chronic multisystem organ failure
* Pregnancy
* Clinically significant Abnormalities on pre-treatment laboratory evaluation
* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.
* Continued drug abuse
* Pre-menopausal women not using contraception
* Previous organ transplant
* Hypersensitivity to sulfur
Effect of Aromatase Inhibitors on Breast Magnetic Resonance Imaging (MRI)

This study is a primary investigation to determine the usefulness and safety of a short course of a relatively high dose of letrozole (a medication used to decrease the female hormone estrogen which is produced locally inside the breast after menopause) in improving the performance of of breast MRI (Magnetic Resonance Imaging). The inhibition of estrogen in the breast by letrozole might help better identifying of suspicious areas in the breast and could assist radiologists in distinguishing between benign breast areas and cancer tissue. This might help reducing the rate of call backs and unnecessary biopsies for patients. We expect to enroll 20 healthy postmenopausal women in this study.

A breast MRI will be performed in the standard way for diagnosis and to serve as a baseline. A second MRI will be performed within a month and following administration of letrozole 12.5 mg daily for three days to reduce breast estrogen levels and in anticipation of lowering breast gadolinium dye uptake.

Eligibility Criteria:
Inclusion Criteria:

* Women are eligible to participate if they are 40 years or older and have been menopausal (had no menstrual bleeding during the past 12 months)

Exclusion Criteria:

* History of bilateral mastectomy, osteoporosis or renal impairment.
The Influence of Neuromuscular Reversal on Neurological Physical Exam Time in Lumbar Neurosurgical Cases.

Neurological physical exam is a very important outcome that should be evaluated as soon as possible after every lumbar procedures. The aim of this study was to evaluate the neurological physical examination time after lumbar procedures.

Neurological physical exam is a very important outcome that should be evaluated as soon as possible after every lumbar procedures. By that early postoperative neurological complications can be revealed and early interventions planned. The aim of this study was to evaluate the neurological physical examination time after lumbar procedures. Two routinely used different reversal agents (neostigmine or sugammadex) were compared according reversal times and muscle strength on PACU admission.

Eligibility Criteria:
Inclusion Criteria:

* Lumber surgery
* ASA I-II
* Elective surgery

Exclusion Criteria:

* Emergency cases
* Age lower than 18
* Age higher than 65
* Patient with existing neurological deficit
* Patient with existing renal insufficiency
Clinical Study On Extracorporeal Shock Wave Therapy For Rotator Cuff Injuries

This clinical trial aims to learn about the effect of extracorporeal shock wave therapy on rotator cuff injuries. The main question it aims to answer is the efficacy of extracorporeal shock wave therapy on the improvement of pain, shoulder function, and quality of life in patients with rotator cuff injuries. The experimental group of patients received extracorporeal shock wave therapy combined with conventional rehabilitation therapy. The control group only received conventional rehabilitation therapy. Compare the two groups to explore the therapeutic effect of extracorporeal shock wave therapy on rotator cuff injuries.


Eligibility Criteria:
Inclusion Criteria:

* Meet the diagnostic criteria of rotator cuff injuries in 2019 American Academy of Orthopaedic Surgeons Clinical Practice Guideline for rotator Cuff Injuries (diagnostic criteria: （1）The clinical signs included positive empty cup test and full cup test, positive internal rotation resistance test in abduction and external rotation position and positive Jobe sign in lateral position. (2) Imaging: magnetic resonance imaging, magnetic resonance arthrography or ultrasound showed rotator cuff injuries, including supraspinatus, infraspinatus, teres minor and subscapularis tendon injuries);
* Definite imaging diagnosis: magnetic resonance imaging, magnetic resonance arthrography or ultrasound examination;
* The shoulder joint did not receive surgical treatment;
* Both sexes, aged 20-80 years old;
* Stable vital signs, good communication, and active cooperation to complete the relevant evaluation and treatment;
* Informed consent was obtained from patients or their families before treatment.

Exclusion Criteria:

* MRI showed medium, large and huge full-thickness rotator cuff tears;
* Skin damage or skin disease at the application site;
* Previous history of shoulder surgery;
* Pregnant or lactating women;
* Allergic constitution;
* Patients with primary diseases of the heart, liver, kidney, or hematopoietic system, patients with mental disorders, patients with built-in cardiac pacemaker, and patients with implanted metal medical devices;
* complicated with other diseases that cause body pain;
* Unable to cooperate with the completion of the whole treatment and follow-up.
Comparative Effects of Rebound Training and Theraband Resistance Exercise in Badminton Players

Comparative Effects of Rebound Training and Theraband Resistance Exercise in Badminton Players With Patellofemoral Pain Syndrome

Comparative Effects of Rebound Training and Theraband Resistance Exercise on agility, power and dynamic balance in Badminton Players With Patellofemoral Pain Syndrome

Eligibility Criteria:
Inclusion Criteria:

* Females
* Age 18 to 25 years
* Positive Patellofemoral Compression Test ( Pain is in around the patella and back of knee cap) With playing experience of 3 years will be included
* Minimum Sports activity 1 hour 4 times a week

Exclusion Criteria:

* Recreational players
* Players with recent injury in past 6 months
* Any musculoskeletal and neurological problem
* Player addicted to any drug or alcohol will be excluded
Individualized, Target-Driven Treatment Of Children With Idiopathic Short Stature

To demonstrate that an individualized, formula-based Genotropin regimen for children with Idiopathic Short Stature will lead to a targeted height gain (to reach the target of 10th percentile (%), or -1.3 SDS) during 24 months of treatment. The endpoint at 4 years is to explore treatment efficiency over four years of two formula-based dose regimens (sub-arms) compared to standard treatment


Eligibility Criteria:
Inclusion Criteria:

* Prepubertal children with bone ages between 3 and 10 years of age for males and 3 and 9 years of age for females
* Naive to Growth Hormone treatment

Exclusion Criteria:

* Abnormal karyotype. Small Gestational Age and Skeletal dysplasia.
Postoperative Virtual Clinical Encounters

Postoperative follow up is necessary following any surgical procedure and has been conducted in the same manner since the field of surgery began. The study will determine feasibility and patient satisfaction of innovative postoperative virtual clinical encounters utilizing mobile video conference technology for women undergoing pelvic reconstructive surgery through a randomized controlled trial.

This will be a prospective randomized control study comparing postoperative virtual clinical encounters versus traditional in-office postoperative visits in women undergoing pelvic reconstructive surgery. The postoperative experiences of both groups will be assessed via surveys. Virtual Clinical Encounter Group: - Receive video-conference call from office nurse 48-72 hours post discharge from hospital - Receive video-conference call from fellow and/or attending physician approximately 30 days (4-6 weeks) from surgery -- Complete telephone survey one day later - Have in-office postoperative visit with fellow and/or attending physician approximately 90 days (10-12 weeks) from surgery -- Fill out surveys after office visit Traditional Office Group: - Receive telephone call from office nurse 48-72 hours post discharge from hospital - Have in-office postoperative visit with fellow and/or attending physician approximately 30 days (4-6 weeks) from surgery -- Complete telephone survey one day later - Have in-office postoperative visit with fellow and/or attending physician approximately 90 days (10-12 weeks) from surgery -- Fill out surveys after office visit

Eligibility Criteria:
Inclusion Criteria:

* Undergoing surgery for pelvic organ prolapse
* Age greater than 18
* Access to a smartphone
* Access to high speed internet access (via 4G or 3G on their smartphone or high speed Wi-Fi)
* Signed up for MyPennMedicine web portal
* Ability to download MyChart mobile application
* Pennsylvania Hospital Subject: NJ or PA resident, HUP \& Presbyterian Hospital Subject: PA resident

Exclusion Criteria:

* Pregnancy
* Inability to read, speak or understand English
* Isolated midurethral sling procedure
* Extraperitoneal vaginal colpopexy with Uphold mesh
A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative Colitis

The purpose of this study is to evaluate the pharmacokinetics (what the body does to the study medication) and safety of subcutaneously (under the skin) administered golimumab in pediatric participants (aged 2 to 17 years) with moderately to severely active Ulcerative Colitis (UC).

This is an open-label (both \[participants and investigator\] know what treatment participants will receive) and multicenter study. The study is divided into 2 parts: Part 1: pharmacokinetics portion (Week 0 to Week 14); Part 2: study extension (Week 14 to Week 114). The focus of this study is to evaluate the pharmacokinetics and safety of golimumab. Additionally the efficacy of short-term therapy with golimumab will be evaluated. Participants in clinical response at Week 6 will continue to receive open label golimumab maintenance therapy and will enter the study extension at Week 14. Participants who are not in clinical response at Week 6 will be withdrawn from further treatment with golimumab. At Week 114, participants who, in the opinion of the investigator, may benefit from continued treatment will be eligible to continue to receive golimumab every 4 weeks until marketing authorization is obtained in the treatment of pediatric UC in that country, or until a decision has been made not to pursue an indication in pediatric UC. Approximately 30 participants will be enrolled in this study. The total duration of study participation for a participant will be approximately 126 weeks or longer.

Eligibility Criteria:
Inclusion criteria:

* Moderate to severe Ulcerative Colitis (UC) defined by a Mayo score (a score used to assess the treatment for UC) of 6 to 12 inclusive, including an endoscopic subscore of 2 or more.
* Must either be currently receiving treatment with, or have a history of having failed to respond to, or have a medical contraindication to at least 1 of the following therapies: oral or intravenous corticosteroids, 6-mercaptopurine and azathioprine OR must either have or have had a history of corticosteroid dependency (ie, an inability to successfully taper corticosteroids without a return of the symptoms of UC) OR required more than 3 courses of corticosteroids in the past year
* No history of latent or active tuberculosis prior to screening
* Positive protective antibody titers to varicella and measles prior to the first administration of study agent

Exclusion criteria:

* Have severe extensive UC that is likely to require a colectomy (surgical removal of the colon) within 12 weeks of study entry
* Have UC limited to the rectum only or to less than 20 cm of the colon
* Presence of a stoma
* Presence or history of a fistula
* Have evidence of Crohn's disease (an inflammatory large intestine disease)
* Previous exposure to anti-tumor necrosis factor therapy
A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic pulmonary fibrosis (IPF) is a serious chronic (long term) disease with injury of lung tissues. REGEND001 is a cell therapy product, made from bronchial basal cells with ability to regenerate lung tissue, is promising to IPF treatment. This is a multi-center, randomized, double-blinded, parallel and placebo-controlled phase II clinical study to evaluate the efficacy and safety of REGEND001 in IPF patients.


Eligibility Criteria:
Inclusion Criteria:

* Male or female, aged between 40 to 75;
* Subjects diagnosed with IPF according to guidelines for the diagnosis of idiopathic pulmonary fibrosis 2022 edition;
* Subjects tolerant to bronchofiberscope;
* Subjects tolerant to test of lung function;
* Subjects able to voluntarily sign the informed consent and cooperate with the completion of pulmonary function tests;

Exclusion Criteria:

* Female subject who is pregnant, nursing, or planning to be pregnant in half a year after using this product (or male subjects planning to have a pregnant spouse);
* At the time of screening, subject who is positive in each of treponema pallidum antibody (TP-Ab), human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody test, except the following: (1) Hepatitis B virus carriers (only HBsAg positive, no hepatitis symptoms and signs, all liver function tests are normal); (2) Cured hepatitis C patients with negative result in HCV ribonucleic acid (RNA) test.
* Subject with malignant tumors or a history of malignant tumors;
* Subject with severe anemia, poorly controlled agranulocytosis and thrombocytopenia at screening;
* Subject at risk of suicide or has a history of mental illness or epilepsy at the time of screening;
* Subject with severe arrhythmias or atrioventricular block of degree II or above, shown by 12-lead Electrocardiogram (ECG);
* Subject who participated in other interventional clinical trials in the past 3 months;
* Subject assessed as inappropriate to participate in this clinical trial by investigators.
Manual Therapy on the Improvement of Functional Disability in Patients With Chronic Non Specific Low Back Pain

Background: Models have tried to explain the driving mechanisms behind chronic non specific low back pain (CNSLBP) in order to propose better appropriate conservative treatment. Altered responses at spinal and/or supraspinal level may affect the perception of pain and degree of disability of CNSLBP patients. Recent clinical recommendations still propose active exercises (AE) for CNSLBP. However, acceptance of exercises by patients may be limited by pain-related manifestations. Current evidences suggest manual therapy (MT) induces a short-term analgesic effect through neurophysiological mechanisms at peripheral, spinal and cortical levels. The aim of this study was first, to assess whether MT has an instant analgesic effect, and second, to compare the long-lasting effect on functional disability of MT followed by AE to sham therapy (ST) followed by AE. Methods: Forty-two CNSLBP patients without co-morbidities, randomly distributed into 2 treatment groups, received either spinal manipulation/mobilization (first intervention) plus AE (MT group; n = 22), or detuned ultrasound (first intervention) plus AE (ST group; n = 20). Eight therapeutic sessions were delivered over 4 to 8 weeks. Instant analgesic effect was obtained by measuring pain intensity (Visual Analogue Scale) before and immediately after the first intervention of each therapeutic session. Pain intensity, disability (Oswestry Disability Index) and fear-avoidance beliefs (Fear-Avoidance Beliefs Questionnaire) were determined before treatment, after the 8th therapeutic session, and at 3- and 6-month follow-ups.


Eligibility Criteria:
Inclusion Criteria:

* suffering from non specific low back pain with or without symptoms in the lower extremity for a period between 12 and 26 weeks
* can maintain the usual medication

Exclusion Criteria:

* spinal fracture or surgery within the previous 6 months
* pregnancy
* neoplasia
* spinal infection
* spinal inflammatory arthritis
* low back pain of visceral origin
* severe sensitive and/or motor radicular deficit from nerve root origin of less than 6 months
* score of 3/5 or more on the Waddell Score
* on sick leaves from work for 6 months or more
* psychiatric disorders
* opioid medication
* patient unable to collaborate (linguistic barrier; cognitive impairments)
* radiologic abnormalities other than degenerative disease
* clinical neurogenic claudication.
The Effect of Exposure to Aversive Non-verbal Vocalizations on Pain Tolerance

Humans produce non-verbal vocalizations (shouting, growling, screaming), laughter, ...) in various contexts that are likely to perform biological functions.

and important social issues. Yet despite their importance in the human vocal repertoire, the mechanisms and functions of non-verbal vocalizations remain little studied and poorly understood including in humans.

In this context, the investigators wish to examine how the perception of vocalizations non-verbal aversive behaviours influence pain tolerance in healthy adults.

Humans produce nonverbal vocalisations such as screams, grunts, roars, cries and laughter across a variety of contexts. Yet despite the prominence and apparent importance of these nonverbal sounds in human communication, the investigators still know very little about their influence on human perception and behaviour. That's why, in this study, the investigators will examine specifically the influence of nonverbal vocal perception on pain tolerance.

The remainder of the study will involve up to three trials of a pain tolerance (cold pressor) task, during which the investigators will ask participants to listen to vocalisations (e.g., babies' cries or babbling) while submerging the participant's hand in bath of circulating cold water.

The results of the study will contribute to theoretical understanding of the functions of nonverbal vocal communication in humans, in particular the influence of nonverbal vocal and perception (of babies' cries) on pain tolerance.

Eligibility Criteria:
Inclusion Criteria:

* Participant in good health
* Affiliated or entitled participant in a social security scheme
* Participant who received informed information about the study and co-signed, with the investigator, a consent to participate in the study

Exclusion Criteria:

* Chronic pain
* High blood pressure or poor circulation
* Cardiac or vascular disease, or a heart condition (including symptoms of Raynaud's syndrome)
* Allergy or hypersensitivity to cold
* Diabetes
* Epilepsy
* Pregnancy
* Recent serious injury
* Neurological or psychiatric condition known to affect pain tolerance (e.g., peripheral neuropathy, schizophrenia)
* History of fainting or seizures
* History of frostbite
Differences Between Male and Femal Fetal Brain Biometry by Ultrasound

Differences of fetal brain biometry as Biparietal diameter,Head circumference,Transcerebellar diameter, Cavum septum pellucidum as regard to fetal gender by ultrasound


Eligibility Criteria:
Inclusion Criteria:

* healthy women from 18 to 36 weeks gestation of pregnant cases aged from 18 to 40 years normal body mass index range from 18 to 25

Exclusion Criteria:

* Pregnant women with any chronic or systemic disease and fetuses with chromosome anomalies or developmental retardation were not included in the study
Immunonutrition Versus Standard Enteral Nutrition Before Major Surgery

The aim of this trial is to compare preoperative Imunnonutrition with standard enteral nutrition regarding morbidity after major abdominal surgery in patients with NRS greater 3.

The primary end point is the complication rate until 30 days after surgery.

Malnutrition affects about 20-50% of all patients in hospital \[1, 2\]. Major surgery further increases postoperative malnutrition and immunity reduction. Therefore, postoperative complication and infection rates after major surgery exceed 30% \[3-6\].

The nutritional risk score (NRS) \[1\] is based on the ESPEN (European society of parenteral and enteral nutrition) screening guidelines and identifies patients who are likely to benefit from nutritional support. Patients with a NRS ≥ 3 are considered severely undernourished, or to have a certain degree of severity of disease in combination with certain degree of malnutrition \[7\].

In a prospective cohort study patients with a NRS ³ 3 had significant more infectious and overall complications after major abdominal surgery \[4, 7, 8\]. Several studies showed a benefit by nutritional support on complications \[3, 5, 6\]. International guidelines suggest therefore preoperative oral nutritional support for malnourished patients undergoing major surgery \[9\]. However, it remains controversial whether standard enteral nutrition (SEN) or immunonutrition (IN) is preferable \[9\].

IN, containing arginine, ribonucleic acid and omega-3 polyunsaturated fatty acids aims to improve the nutritional status, immunological function and clinical outcome \[5, 10\].

Eligibility Criteria:
Inclusion Criteria:

* All patients admitted for elective major abdominal surgery:

  * Open and laparoscopic esophageal, gastric, hepatic, pancreatic, intestinal and colorectal surgery and with a NRS ≥ 3.

Exclusion Criteria:

* Age \< 18 years
* No informed consent
* Emergency situation
* Patients not speaking french or german.
Single-port Laparoscopy in Children and Adolescents

To compare the safety evaluation, efficacy evaluation, long-term aesthetics and psychological satisfaction of single-port and multiport laparoscopy for children and adolescents with BOT in China.


Eligibility Criteria:
Inclusion Criteria:

* Patients ≤18 years old
* Postoperative pathological diagnosis confirmed benign ovarian tumor
* Multi-hole laparoscopic or single-hole laparoscopic surgery
* Medical records and pathological data were complete and available

Exclusion Criteria:

* Patients with malignant pathological diagnosis
* Patients undergoing open surgery
* Incomplete medical records or pathological data